Accreditation Expired
NASH: Advances in non-invasive screening
GlobalAn overview of the latest in non-invasive screening for NASH
NASH: Advances in non-invasive screening
NASH occurs in around 20% of individuals with NAFLD, and puts patients at high risk of poor outcomes including cardiovascular events and hepatocellular carcinoma. With people with type 2 diabetes and obesity at significantly increased risk for developing NAFLD, how can we identify those with NASH?
In this video, Dr Kenneth Cusi presents the latest advances in using non-invasive biomarkers and imaging techniques to screen people for advanced fibrosis.
By completing this module you can qualify for 0.25 CME credits. To claim your credits, you must watch the video and successfully pass the post-module assessment.
Pre-Activity Information
Hepatologists, endocrinologists, diabetologists, gastroenterologists, GPs
This educational activity is intended for an international audience of non-US and non-UK HCPs.
After taking part in this activity, learners will be able to identify non-invasive screening strategies and biomarkers for identifying patients at risk of advanced fibrosis / NASH
Faculty: Dr. Kenneth Cusi
| Type of affiliation / financial interest | Name of commercial company |
|---|---|
| Research Support | Poxel, Zydus, Echosens, Inventiva, Novo Nordisk |
| Consultant | Allergan, Altimmune, Arrowhead, AstraZeneca, BMS, Boehringer Ingelheim, Coherus, Eli Lilly, Genentech, Gilead, Intercept, Janssen, Pfizer, Prosciento, Madrigal, and Novo Nordisk. |
Staff Disclosures
Liberum IME staff, ACHL staff and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.
This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S has had no influence on the content of this education.
This module was accredited on the 17th May 2022 and will expire on the 17th May 2023.
The information and data provided in this program was updated and correct at the time of the program development, but may be subject to change.